A Phase 3 interventional study of placebo and BIBF 1120 in Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 108 sites in 17 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-07-25.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Pulmonary Fibrosis with a site in United States — 30 open to participants now, 42 under way, 5 of them phase 3. Pulmonary Fibrosis · United States.
Among the 128 studies in Pulmonary Fibrosis with a site in United States, this one is the 6th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2011, is one of 15 in phase 3, and was the 47th registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →30 of the 128 studies in Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
PureTech · Sites in United States, Canada
Ages 40+
Peter Caravan · Sites in United States
Ages 18–80
University of Wisconsin, Madison · Sites in United States
Ages 18+
Cedars-Sinai Medical Center · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 48 · Phase 3 17 · Phase 4 3
First in 1978; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 551 is above the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.
Median enrollment 50 across the 90 interventional studies, 200 across the 37 observational. Of the 76 that completed or were terminated, 37 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 128 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 9 studies filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Pulmonary Fibrosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04948203Phase 3University of ChicagoAssessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | 2026-12 |
| NCT00515567University of ChicagoExplanted Lung Tissues With Pulmonary Fibrosis | 2026-12 |
| NCT06567717Cedars-Sinai Medical CenterZinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis | 2027-01 |
| NCT04964115Vanderbilt University Medical CenterPost Acute Sequelae of COVID-19 | 2027-05-31 |
| NCT06329401Avalyn Pharma Inc.A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 128 studies in Pulmonary Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the death rate.
In a large Phase 2 trial (1199.30) (NCT00514683), investigating the effects of 52 weeks of treatment with BIBF 1120 in patients with IPF, a positive effect was seen on lung function of patients treated with high dose of BIBF 1120 compared to placebo.
Hence it is the purpose of this trial to investigate and confirm the efficacy and safety of BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will be conducted as a prospective, randomised design with the aim to collect safety and efficacy data.
Respiratory function is globally accepted for assessment of treatment effects in IPF patients. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in IPF patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient receives capsules identical to those containing active drug
Drug: placebo
patient receives capsules containing BIBF 1120 twice a day
Drug: BIBF 1120
placebo matching BIBF 1120 BID
BIBF 1120 BID (twice daily)
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. For this endpoint reported means represent the adjusted rate.
Time frame: 52 weeks
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks
This is a key secondary endpoint. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact. The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status. Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Time frame: Baseline and 52 weeks
Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows: Otherwise unexplained clinical features including all of the following: Unexplained worsening or development of dyspnoea within 30 days New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit Exclusion of infection as per routine clinical practice and microbiological studies Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury. Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs .
Time frame: 52 weeks
Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Time frame: Baseline and 52 weeks
Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Time frame: Baseline and 52 weeks
Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Time frame: Baseline and 52 weeks
Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Time frame: Baseline and 52 weeks
Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold
Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by \>5%, increase by \>5%, and change within ≤5%).
Time frame: Baseline and 52 weeks
Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold
Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by \>10%, and change within ≤10%)
Time frame: Baseline and 52 weeks
FVC Responders Using 10% Threshold at 52 Weeks
FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.
Time frame: 52 weeks
Proportion of FVC Responders Using 5% Threshold at 52 Weeks
Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.
Time frame: 52 weeks
Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)
Proportion of SGRQ responders at 52 weeks. Responders defined as \<= -4 points change in change from baseline in SGRQ total score at 52 weeks.
Time frame: baseline and 52 weeks
Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Time frame: baseline and 52 weeks
Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Time frame: baseline and 52 weeks
Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Time frame: baseline and 52 weeks
Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score. The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.
Time frame: baseline and 52 weeks
Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)
Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Time frame: baseline and 52 weeks
Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Time frame: baseline and 52 weeks
Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
The cough domains of the Cough and Sputum Assessment Questionnaire (CASA- Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Time frame: baseline and 52 weeks
Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)
Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.
Time frame: 52 weeks
Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)
The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.
Time frame: baseline, 12 weeks, 24 weeks and 52 weeks
Risk of an Acute IPF Exacerbation Over 52 Weeks
The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years\*100)
Time frame: 52 weeks
Time to Death Over 52 Weeks
Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died over 52 weeks (373 days time-period).
Time frame: 52 weeks
Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period).
Time frame: 52 weeks
Time to On-treatment Death
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported. Failure is the the proportion of patients who died on-treatment.
Time frame: 52 weeks
Time to Death or Lung Transplant Over 52 Weeks
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period).
Time frame: 52 weeks
Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria: FVC \<45% predicted or Carbon monoxide diffusion capacity (DL(CO)) \<30% pred or Oxygen saturation on pulse oximetry (SpO2) \<88% at rest, at sea level (to be adapted for other heights). These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).
Time frame: 52 weeks
Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks
Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)
Time frame: baseline and 52 weeks
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Time frame: baseline and 52 weeks
| Milestone | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Started | 220 | 331 |
| Completed | 179 | 272 |
| Not completed | 41 | 59 |
| Withdrew: Adverse event | 30 | 42 |
| Withdrew: Non compliant with protocol | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Consent withdrawn, not due to ae | 7 | 9 |
| Withdrew: Not treated | 1 | 2 |
| Withdrew: Reason other than those stated above | 2 | 2 |
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. For this endpoint reported means represent the adjusted rate.
| mL/year | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks. | -207.32 ± 19.309 | -113.59 ± 15.726 |
This is a key secondary endpoint. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact. The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status. Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
| points on a scale | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks | 5.48 ± 0.891 | 2.80 ± 0.730 |
Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows: Otherwise unexplained clinical features including all of the following: Unexplained worsening or development of dyspnoea within 30 days New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit Exclusion of infection as per routine clinical practice and microbiological studies Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury. Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs .
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Failure | 9.6 | 3.6 |
| Censored | 90.4 | 96.4 |
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
| mL | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks | -205.03 ± 16.629 | -95.26 ± 14.200 |
Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
| percent change | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks | -8.14 ± 0.620 | -3.90 ± 0.528 |
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
| %predicted | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks | -6.15 ± 0.505 | -3.09 ± 0.433 |
Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
| percent change | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks | -8.13 ± 0.614 | -3.92 ± 0.525 |
Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by \>5%, increase by \>5%, and change within ≤5%).
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Decrease > 5% | 52.2 | 34.9 |
| Change within ≤ 5% | 45.0 | 50.2 |
| Increase > 5% | 2.8 | 14.9 |
Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by \>10%, and change within ≤10%)
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Decrease > 10% | 22.2 | 14.9 |
| Change within ≤ 10% | 77.2 | 80.7 |
| Increase > 10% | 0.6 | 4.5 |
FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| FVC Responders Using 10% Threshold at 52 Weeks | 63.93 (57.38 to 70.00) | 69.60 (64.43 to 74.33) |
Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Proportion of FVC Responders Using 5% Threshold at 52 Weeks | 39.27 (33.04 to 45.87) | 53.19 (47.79 to 58.52) |
Proportion of SGRQ responders at 52 weeks. Responders defined as \<= -4 points change in change from baseline in SGRQ total score at 52 weeks.
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs) | 16.89 (12.51 to 22.42) | 25.23 (20.84 to 30.19) |
SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
| points on a scale | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs) | 3.43 ± 1.297 | 2.03 ± 1.061 |
SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
| points on a scale | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs) | 5.93 ± 1.036 | 2.85 ± 0.852 |
SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
| points on a scale | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs) | 7.20 ± 1.052 | 3.89 ± 0.863 |
SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score. The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.
| points on a scale | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs) | 5.84 ± 0.921 | 2.72 ± 0.757 |
Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
| points on a scale | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs) | 9.07 ± 1.300 | 6.69 ± 1.073 |
The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
| points on a scale | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs) | -2.38 ± 1.325 | -0.33 ± 1.087 |
The cough domains of the Cough and Sputum Assessment Questionnaire (CASA- Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
| points on a scale | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs) | -4.39 ± 1.209 | -2.58 ± 0.991 |
Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs) | 53.88 (47.27 to 60.36) | 61.70 (56.34 to 66.79) |
The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.
| points on a scale | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| 12 weeks (N=207, 306) | -1.48 ± 15.60 | -0.57 ± 16.97 |
| 24 weeks (N=204, 297) | -4.86 ± 16.94 | -1.10 ± 16.81 |
| 52 weeks (N=178, 265) | -5.60 ± 17.67 | -2.52 ± 16.95 |
The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years\*100)
| Participants/Year *100 | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Risk of an Acute IPF Exacerbation Over 52 Weeks | 10.2 | 3.9 |
Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died over 52 weeks (373 days time-period).
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Failure | 9.1 | 6.7 |
| Censored | 90.9 | 93.3 |
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period).
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Failure | 5.0 | 4.3 |
| Censored | 95.0 | 95.7 |
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported. Failure is the the proportion of patients who died on-treatment.
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Failure | 7.8 | 4.9 |
| Censored | 92.2 | 95.1 |
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period).
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Failure | 10.0 | 6.7 |
| Censored | 90.0 | 93.3 |
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria: FVC \<45% predicted or Carbon monoxide diffusion capacity (DL(CO)) \<30% pred or Oxygen saturation on pulse oximetry (SpO2) \<88% at rest, at sea level (to be adapted for other heights). These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).
| percentage of participants | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Failure | 23.7 | 19.5 |
| Censored | 76.3 | 80.5 |
Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)
| percent of oxygen saturation | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks | -0.66 ± 0.174 | -0.39 ± 0.149 |
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
| mmol/min/kPa | Placebo | Nintedanib 150 mg Bid |
|---|---|---|
| Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks | -0.400 ± 0.0843 | -0.286 ± 0.0729 |
Collected over From the first drug administration until 28 days after the last drug administration, up to 425 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 72/219 (32.9%) | 193/219 (88.1%) |
| Nintedanib 150mg Bid | — | 98/329 (29.8%) | 308/329 (93.6%) |
| Event | Placebo | Nintedanib 150mg Bid |
|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 28/219 | 22/329 |
| PneumoniaInfections and infestations | 11/219 | 18/329 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 5/219 | 2/329 |
| BronchitisInfections and infestations | 0/219 | 6/329 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 3/219 | 6/329 |
| Respiratory tract infectionInfections and infestations | 3/219 | 1/329 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/219 | 2/329 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 3/219 | 4/329 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/219 | 4/329 |
| AnaemiaBlood and lymphatic system disorders | 2/219 | 0/329 |
| Event | Placebo | Nintedanib 150mg Bid |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 39/219 | 207/329 |
| NauseaGastrointestinal disorders | 16/219 | 86/329 |
| NasopharyngitisInfections and infestations | 34/219 | 48/329 |
| CoughRespiratory, thoracic and mediastinal disorders | 31/219 | 38/329 |
| Decreased appetiteMetabolism and nutrition disorders | 10/219 | 42/329 |
| Weight decreasedInvestigations | 2/219 | 37/329 |
| Upper respiratory tract infectionInfections and infestations | 24/219 | 30/329 |
| VomitingGastrointestinal disorders | 7/219 | 34/329 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 22/219 | 25/329 |
| FatigueGeneral disorders | 20/219 | 26/329 |
Treated Set (TS): The TS consisted of randomized patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.
| Age, Continuous(years) | Placebo | Nintedanib 150 mg Bid | Total |
|---|---|---|---|
| Mean | 67.1 ± 7.5 | 66.4 ± 7.9 | 66.6 ± 7.8 |
| Sex: Female, Male(Participants) | Placebo | Nintedanib 150 mg Bid | Total |
|---|---|---|---|
| Female | 48 | 73 | 121 |
| Male | 171 | 256 | 427 |
Showing the first 100 of 108 sites across 17 countries. Choose a country and city above to see the rest.
The record gives a start of May 2011, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year 4 months after primary completion. A results delay was requested in Mar 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib